BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A 3rd, Nemcek AA Jr, Gates VL, Abecassis M, Omary RA, Salem R. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71-81. [PMID: 18027884 DOI: 10.1002/hep.21980] [Cited by in Crossref: 401] [Cited by in F6Publishing: 362] [Article Influence: 28.6] [Reference Citation Analysis]
Number Citing Articles
1 Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012;10:354-362. [PMID: 22083023 DOI: 10.1016/j.cgh.2011.11.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
2 Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol 2014;4:S112-21. [PMID: 25755602 DOI: 10.1016/j.jceh.2014.03.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
3 Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-Improvement Guidelines for Hepatic Transarterial Chemoembolization. Cardiovasc Intervent Radiol 2012;35:765-74. [DOI: 10.1007/s00270-012-0423-z] [Reference Citation Analysis]
4 Lee J, Yeganeh B, Ermini L, Post M. Sphingolipids as cell fate regulators in lung development and disease. Apoptosis 2015;20:740-57. [PMID: 25753687 DOI: 10.1007/s10495-015-1112-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
5 Khorsandi SE, Heaton N. Contemporary strategies in the management of hepatocellular carcinoma. HPB Surg 2012;2012:154056. [PMID: 23197879 DOI: 10.1155/2012/154056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
6 Kim H, Chung JW, Lee IJ, An S, Seong NJ, Son KR, Jae HJ, Park JH. Intercostal Artery Supplying Hepatocellular Carcinoma: Demonstration of a Tumor Feeder by C-arm CT and Multidetector Row CT. Cardiovasc Intervent Radiol 2011;34:87-91. [DOI: 10.1007/s00270-010-9883-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
7 Munene G, Vauthey JN, Dixon E. Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC. Int J Hepatol. 2011;2011:565060. [PMID: 21994863 DOI: 10.4061/2011/565060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
8 Pan JJ, Javle M, Thinn MM, Hsueh CT, Hsueh CT. Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. Hepat Med 2010;2:147-55. [PMID: 24367212 DOI: 10.2147/HMER.S7123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
9 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Kennedy A. Radioembolization of hepatic tumors. J Gastrointest Oncol. 2014;5:178-189. [PMID: 24982766 DOI: 10.3978/j.issn.2078-6891.2014.037] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
11 Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350-391. [PMID: 19406039 DOI: 10.6004/jnccn.2009.0027] [Cited by in Crossref: 299] [Cited by in F6Publishing: 324] [Article Influence: 23.0] [Reference Citation Analysis]
12 Cucchetti A, Cappelli A, Ercolani G, Mosconi C, Cescon M, Golfieri R, Pinna AD. Selective Internal Radiation Therapy (SIRT) as Conversion Therapy for Unresectable Primary Liver Malignancies. Liver Cancer. 2016;5:303-311. [PMID: 27781202 DOI: 10.1159/000449341] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
13 Duke E, Deng J, Ibrahim SM, Lewandowski RJ, Ryu RK, Sato KT, Miller FH, Kulik L, Mulcahy MF, Larson AC. Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol. 2010;21:515-521. [PMID: 20172741 DOI: 10.1016/j.jvir.2009.11.020] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
14 Cardarelli-Leite L, Chung J, Klass D, Marquez V, Chou F, Ho S, Walton H, Lim H, Tae Wan Kim P, Hadjivassiliou A, Liu DM. Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol 2020;43:411-22. [PMID: 31909439 DOI: 10.1007/s00270-019-02404-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
15 Tabone M, Calvo A, Russolillo N, Langella S, Carbonatto P, Lo Tesoriere R, Richetta E, Pellerito R, Ferrero A. Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience. J Gastrointest Oncol 2020;11:84-90. [PMID: 32175109 DOI: 10.21037/jgo.2019.06.01] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
16 Cappelli A, Sangro P, Mosconi C, Deppe I, Terzi E, Bilbao JI, Rodriguez-Fraile M, De Benedittis C, Ricke J, Golfieri R, Sangro B. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Eur J Nucl Med Mol Imaging 2019;46:661-8. [PMID: 30209522 DOI: 10.1007/s00259-018-4152-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Deleporte A, Flamen P, Hendlisz A. State of the art: radiolabeled microspheres treatment for liver malignancies. Expert Opin Pharmacother 2010;11:579-86. [PMID: 20163269 DOI: 10.1517/14656560903520916] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
18 Edeline J, Crouzet L, Campillo-gimenez B, Rolland Y, Pracht M, Guillygomarc’h A, Boudjema K, Lenoir L, Adhoute X, Rohou T, Boucher E, Clément B, Blanc J, Garin E. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging 2016;43:635-43. [DOI: 10.1007/s00259-015-3210-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
19 Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky V, Tamrazi A, Gebauer B, Schlachter T, Pawlik TM, Geschwind JF. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol 2017;27:526-35. [PMID: 27277261 DOI: 10.1007/s00330-016-4445-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
20 Kulik L. Is radioembolization ready for the barcelona clinic liver cancer staging system? Hepatology 2010;52:1528-30. [DOI: 10.1002/hep.24030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Gebski V, Gibbs E, Gandhi M, Chatellier G, Dinut A, Pereira H, Chow PK, Vilgrain V. VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials. JMIR Res Protoc 2017;6:e17. [PMID: 28202430 DOI: 10.2196/resprot.7016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
22 Ali SM. Radioembolization for hepatocellular carcinoma using TheraSphere®. Saudi J Gastroenterol 2011;17:215-7. [PMID: 21546728 DOI: 10.4103/1319-3767.80388] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Bult W, Seevinck PR, Krijger GC, Visser T, Kroon-Batenburg LM, Bakker CJ, Hennink WE, van het Schip AD, Nijsen JF. Microspheres with ultrahigh holmium content for radioablation of malignancies. Pharm Res 2009;26:1371-8. [PMID: 19240985 DOI: 10.1007/s11095-009-9848-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
24 Lin CC, Hung CF, Chen WT, Lin SM. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. Liver Cancer 2015;4:228-40. [PMID: 26734578 DOI: 10.1159/000367737] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
25 Cheung TT, Kwok PC, Chan S, Cheung CC, Lee AS, Lee V, Cheng HC, Chia NH, Chong CCN, Lai TW, Law ALY, Luk MY, Tong CC, Yau TCC. Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. Liver Cancer 2018;7:40-54. [PMID: 29662832 DOI: 10.1159/000485984] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
26 Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol. 2011;21:294-302. [PMID: 21939859 DOI: 10.1016/j.semradonc.2011.05.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
27 Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma 2020;7:117-31. [PMID: 32984089 DOI: 10.2147/JHC.S248314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, van de Velde C. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol. 2009;20 Suppl 7:vii1-vii6. [PMID: 19497945 DOI: 10.1093/annonc/mdp281] [Cited by in Crossref: 54] [Cited by in F6Publishing: 64] [Article Influence: 4.2] [Reference Citation Analysis]
29 Lam T, Wong W, Lee C, Cheung C. Transarterial chemoembolisation plus stereotactic body radiotherapy as conversion therapy for large right lobe hepatocecullar carcinoma. Surgical Practice 2021;25:211-7. [DOI: 10.1111/1744-1633.12530] [Reference Citation Analysis]
30 Toesca DAS, Barry A, Sapisochin G, Beecroft R, Dawson L, Owen D, Mouli S, Lewandowski R, Salem R, Chang DT. Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:295-308. [PMID: 30309640 DOI: 10.1016/j.semradonc.2018.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Yim SY, Chun HS, Lee JS, Lim J, Kim TH, Kim BK, Kim SU, Park JY, Ahn SH, Kim GM, Won JY, Seo YS, Kim YH, Um SH, Kim DY. Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. Cancers 2022;14:385. [DOI: 10.3390/cancers14020385] [Reference Citation Analysis]
32 Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73. [DOI: 10.1002/hep.23725] [Cited by in Crossref: 323] [Cited by in F6Publishing: 320] [Article Influence: 26.9] [Reference Citation Analysis]
33 Kennedy AS, Sangro B. Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep. 2014;16:373. [PMID: 24488546 DOI: 10.1007/s11912-013-0373-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
34 Ho CL, Chen S, Cheung SK, Leung TWT. Significant Value of 11C-Acetate and 18F-Fluorodeoxyglucose PET/Computed Tomography on 90Y Microsphere Radioembolization for Hepatocellular Carcinoma. PET Clinics 2019;14:459-67. [DOI: 10.1016/j.cpet.2019.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
35 Yim SY, Kim JD, Jung JY, Kim CH, Seo YS, Yim HJ, Um SH, Ryu HS, Kim YH, Kim CS, Shin E. Gastrectomy for the treatment of refractory gastric ulceration after radioembolization with 90Y microspheres. Clin Mol Hepatol 2014;20:300-5. [PMID: 25320734 DOI: 10.3350/cmh.2014.20.3.300] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
36 Kim JH, Shim JH, Yoon HK, Ko HK, Kim JW, Gwon DI. Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein. Liver Int 2018;38:1646-54. [PMID: 29436101 DOI: 10.1111/liv.13719] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
37 Terzi E, Piscaglia F, Forlani L, Mosconi C, Renzulli M, Bolondi L, Golfieri R; BLOG-Bologna Liver Oncology Group, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. TACE performed in patients with a single nodule of hepatocellular carcinoma. BMC Cancer 2014;14:601. [PMID: 25139639 DOI: 10.1186/1471-2407-14-601] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
38 Saini A, Wallace A, Alzubaidi S, Knuttinen MG, Naidu S, Sheth R, Albadawi H, Oklu R. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma. J Clin Med 2019;8:E55. [PMID: 30621040 DOI: 10.3390/jcm8010055] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
39 Riaz A, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora R, Kulik L, Desai K, Thornburg B, Mouli S, Hickey R, Miller FH, Yaghmai V, Ganger D, Lewandowski RJ, Salem R. Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses: Riaz et al. Hepatology 2018;67:873-83. [DOI: 10.1002/hep.29480] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
40 Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G; SARAH Trial Group. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials 2014;15:474. [PMID: 25472660 DOI: 10.1186/1745-6215-15-474] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
41 Buell JF, Thomas MT, Rudich S, Marvin M, Nagubandi R, Ravindra KV, Brock G, McMasters KM. Experience with more than 500 minimally invasive hepatic procedures. Ann Surg. 2008;248:475-486. [PMID: 18791368 DOI: 10.1097/sla.0b013e318185e647] [Cited by in Crossref: 76] [Cited by in F6Publishing: 102] [Article Influence: 5.4] [Reference Citation Analysis]
42 Merle P, Mornex F. [Nonsurgical management of hepatocellular carcinoma]. Cancer Radiother 2010;14:469-73. [PMID: 20739209 DOI: 10.1016/j.canrad.2010.07.228] [Reference Citation Analysis]
43 Zhang ZM, Lai EC, Zhang C, Yu HW, Liu Z, Wan BJ, Liu LM, Tian ZH, Deng H, Sun QH, Chen XP. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg 2015;20:8-16. [PMID: 26026424 DOI: 10.1016/j.ijsu.2015.05.009] [Cited by in Crossref: 60] [Cited by in F6Publishing: 72] [Article Influence: 8.6] [Reference Citation Analysis]
44 Gonsalves CF, Brown DB, Carr BI. Regional radioactive treatments for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008;2:453-6. [PMID: 19072393 DOI: 10.1586/17474124.2.4.453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
45 Mahnken AH. (90)Y-glass microspheres for hepatic neoplasia. Future Oncol 2015;11:1343-54. [PMID: 25952780 DOI: 10.2217/fon.15.12] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Rahman SI, Nunez-Herrero L, Berkes JL. Position 2: Transarterial Radioembolization Should Be the Primary Locoregional Therapy for Unresectable Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2020;15:74-6. [PMID: 32226620 DOI: 10.1002/cld.908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
47 Cuneo KC, Davis MA, Feng MU, Novelli PM, Ensminger WD, Lawrence TS. Low dose rate radiosensitization of hepatocellular carcinoma in vitro and in patients. Transl Oncol 2014;7:472-8. [PMID: 24956939 DOI: 10.1016/j.tranon.2014.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
48 Jia Z, Jiang G, Tian F, Zhu C, Qin X. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Saudi J Gastroenterol. 2016;22:353-359. [PMID: 27748320 DOI: 10.4103/1319-3767.191139] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
49 Xing M, Kokabi N, Camacho JC, Kooby DA, El-Rayes BF, Kim HS. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. J Comp Eff Res 2013;2:435-44. [PMID: 24236684 DOI: 10.2217/cer.13.37] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
50 Fujiki M, Aucejo F, Kim R. General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option? Liver Int. 2011;31:1081-1089. [PMID: 22008644 DOI: 10.1111/j.1478-3231.2011.02473.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
51 Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262:43-58. [PMID: 22190656 DOI: 10.1148/radiol.11110144] [Cited by in Crossref: 211] [Cited by in F6Publishing: 202] [Article Influence: 21.1] [Reference Citation Analysis]
52 Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O’Neil BH. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010;21:1377-1384. [PMID: 20691606 DOI: 10.1016/j.jvir.2010.04.027] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
53 Duan H, Hoffmann M. [Selective internal radiotherapy (SIRT) of liver tumors]. Radiologe 2015;55:48-52. [PMID: 25519898 DOI: 10.1007/s00117-014-2708-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Fujiki M, Aucejo F, Choi M, Kim R. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: Where do we stand? World J Gastroenterol 2014; 20(18): 5308-5319 [PMID: 24833861 DOI: 10.3748/wjg.v20.i18.5308] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
55 Trinchet J. Carcinome hépatocellulaire : une incidence croissante, une prise en charge « optimisée ». Gastroentérologie Clinique et Biologique 2009;33:830-9. [DOI: 10.1016/j.gcb.2009.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
56 Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191 [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
57 Aliseda D, Martí-Cruchaga P, Zozaya G, Benito A, Lopez-Olaondo L, Rodríguez-Fraile M, Bilbao JI, Hidalgo F, Iñarrairaegui M, Ciria R, Pardo F, Sangro B, Rotellar F. Pure laparoscopic major liver resection after yttrium90 radioembolization: a case-matched series analysis of feasibility and outcomes. Langenbecks Arch Surg 2022. [PMID: 35229168 DOI: 10.1007/s00423-022-02474-z] [Reference Citation Analysis]
58 Donahue LA, Kulik L, Baker T, Ganger DR, Gupta R, Memon K, Abecassis MM, Salem R, Lewandowski RJ. Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 2013;24:74-80. [PMID: 23273699 DOI: 10.1016/j.jvir.2012.09.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
59 McKinley SK, Chawla A, Ferrone CR. Inoperable Biliary Tract and Primary Liver Tumors: Palliative Treatment Options. Surg Oncol Clin N Am 2019;28:745-62. [PMID: 31472917 DOI: 10.1016/j.soc.2019.06.009] [Reference Citation Analysis]
60 Feely M, Tondon R, Gubbiotti M, Stashek KM, Numbere N, Huber AR, Sharma AK, Geller BS, Salaria SN, Gonzalez RS. Gastrointestinal Tract Injury by Yttrium-90 Appears Largely Restricted to Resin Microspheres But Can Occur Years After Embolization. Am J Surg Pathol 2022. [PMID: 35389897 DOI: 10.1097/PAS.0000000000001901] [Reference Citation Analysis]
61 Colombo M, Raoul J, Lencioni R, Galle PR, Zucman-rossi J, Bañares R, Seehofer D, Neuhaus P, Johnson P. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. European Journal of Gastroenterology & Hepatology 2013;25:639-51. [DOI: 10.1097/meg.0b013e32835e33bb] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
62 Real M, Bianchi L, Vilana R, Burrel M, Rimola J. Tratamiento percutáneo e intraarterial del carcinoma hepatocelular. Radiología 2010;52:399-413. [DOI: 10.1016/j.rx.2010.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 Kennedy A, Brown DB, Feilchenfeldt J, Marshall J, Wasan H, Fakih M, Gibbs P, Knuth A, Sangro B, Soulen MC, Pittari G, Sharma RA. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. J Gastrointest Oncol 2017;8:1079-99. [PMID: 29299370 DOI: 10.21037/jgo.2017.09.10] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
64 Schiavon LL, Ejima FH, Menezes MR, Bittencourt PL, Moreira AM, Farias AQ, Chagas AL, Assis AM, Mattos ÂZ, Salomão BC, Terra C, Martins FPB, Carnevale FC, Rezende GFDM, Paulo GA, Pereira GHS, Leal Filho JMDM, Meneses J, Costa LSND, Carneiro MV, Álvares-DA-Silva MR, Soares MVA, Pereira OI, Ximenes RO, Durante RFS, Ferreira VA, Lima VM; Members of the Pannel of the 1st Joint Meeting of the SBH, SOBED and SOBRICE. RECOMMENDATIONS FOR INVASIVE PROCEDURES IN PATIENTS WITH DISEASES OF THE LIVER AND BILIARY TRACT: REPORT OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN SOCIETY OF DIGESTIVE ENDOSCOPY (SOBED) AND BRAZILIAN SOCIETY OF INTERVENTIONAL RADIOLOGY AND ENDOVASCULAR SURGERY (SOBRICE). Arq Gastroenterol 2019;56:213-31. [PMID: 31460590 DOI: 10.1590/S0004-2803.201900000-42] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Aujay G, Debordeaux F, Blanc JF, Lapuyade B, Papadopoulos P, Bordenave L, Trillaud H, Pinaquy JB. 18F-choline PET-computed tomography for the prediction of early treatment responses to transarterial radioembolization in patients with hepatocellular carcinoma. Nucl Med Commun 2021;42:633-8. [PMID: 33660694 DOI: 10.1097/MNM.0000000000001383] [Reference Citation Analysis]
66 Kim YI, Chung JW. Selective or targeted gene/drug delivery for liver tumors: advantages and current status of local delivery. Expert Rev Gastroenterol Hepatol 2008;2:791-802. [PMID: 19090739 DOI: 10.1586/17474124.2.6.791] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
67 Woo HY, Heo J. New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol 2015;21:115-21. [PMID: 26157747 DOI: 10.3350/cmh.2015.21.2.115] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
68 Aujay G, Etchegaray C, Blanc J, Lapuyade B, Papadopoulos P, Pey M, Bordenave L, Trillaud H, Saut O, Pinaquy J. Comparison of MRI-based response criteria and radiomics for the prediction of early response to transarterial radioembolization in patients with hepatocellular carcinoma. Diagnostic and Interventional Imaging 2022. [DOI: 10.1016/j.diii.2022.01.009] [Reference Citation Analysis]
69 Vande Lune P, Abdel Aal AK, Klimkowski S, Zarzour JG, Gunn AJ. Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. J Clin Transl Hepatol 2018;6:175-88. [PMID: 29951363 DOI: 10.14218/JCTH.2017.00045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
70 Gnutzmann D, Kortes N, Sumkauskaite M, Schmitz A, Weiss KH, Radeleff B. Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments. Minim Invasive Ther Allied Technol 2018;27:69-80. [PMID: 29381102 DOI: 10.1080/13645706.2018.1432489] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
71 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol 2013; 5(6): 302-310 [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
72 Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:604-11; quiz e43-44. [PMID: 23357493 DOI: 10.1016/j.cgh.2012.12.039] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
73 Kim YH, Kim do Y. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know. Oncology. 2013;84 Suppl 1:34-39. [PMID: 23428856 DOI: 10.1159/000345887] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
74 Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Ignacio Bilbao J, Maria Ettorre G, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Thorsten Hoffmann R, Izzo F, Iñarrairaegui M, Ludovico Maini C, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Franz Jakobs T, Lastoria S; on behalf of the European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology 2011;54:868-78. [DOI: 10.1002/hep.24451] [Cited by in Crossref: 401] [Cited by in F6Publishing: 366] [Article Influence: 36.5] [Reference Citation Analysis]
75 Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, Morosi C, Lanocita R, Romito R, Chiesa C, Maccauro M, Marchianò A, Mazzaferro V. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol 2018;68:724-32. [PMID: 29331342 DOI: 10.1016/j.jhep.2017.12.026] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 13.3] [Reference Citation Analysis]
76 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol 2015;12:481-9. [PMID: 25985939 DOI: 10.1038/nrclinonc.2015.78] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
77 Bujold A, Dawson LA. Stereotactic radiation therapy and selective internal radiation therapy for hepatocellular carcinoma. Cancer Radiother. 2011;15:54-63. [PMID: 21239204 DOI: 10.1016/j.canrad.2010.11.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
78 Sohn JH, Duran R, Zhao Y, Fleckenstein F, Chapiro J, Sahu S, Schernthaner RE, Qian T, Lee H, Zhao L, Hamilton J, Frangakis C, Lin M, Salem R, Geschwind JF. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clin Gastroenterol Hepatol. 2017;15:746-755.e4. [PMID: 27847278 DOI: 10.1016/j.cgh.2016.10.036] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
79 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
80 Takayasu K. Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective. Oncology 2011;81 Suppl 1:105-10. [PMID: 22212943 DOI: 10.1159/000333269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
81 Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, Hickey R, Kulik L, Ganger D, Flamm S, Atassi R, Atassi B, Sato K, Benson AB, Mulcahy MF, Abouchaleh N, Asadi AA, Desai K, Thornburg B, Vouche M, Habib A, Caicedo J, Miller FH, Yaghmai V, Kallini JR, Mouli S, Lewandowski RJ. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experience. Hepatology 2018;68:1429-40. [DOI: 10.1002/hep.29691] [Cited by in Crossref: 87] [Cited by in F6Publishing: 70] [Article Influence: 21.8] [Reference Citation Analysis]
82 Salman A, Simoneau E, Hassanain M, Chaudhury P, Boucher LM, Valenti D, Cabrera T, Nudo C, Metrakos P. Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma. Curr Oncol 2016;23:e472-80. [PMID: 27803608 DOI: 10.3747/co.23.2827] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
83 Bennink RJ, Cieslak KP, van Delden OM, van Lienden KP, Klümpen HJ, Jansen PL, van Gulik TM. Monitoring of Total and Regional Liver Function after SIRT. Front Oncol 2014;4:152. [PMID: 24982851 DOI: 10.3389/fonc.2014.00152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
84 Marelli L, Shusang V, Buscombe JR, Cholongitas E, Stigliano R, Davies N, Tibballs J, Patch D, Meyer T, Burroughs AK. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med 2009;50:871-7. [PMID: 19443599 DOI: 10.2967/jnumed.108.060558] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
85 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 367] [Article Influence: 91.3] [Reference Citation Analysis]
86 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 0.5] [Reference Citation Analysis]
87 Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, Ryu RK, Sato KT, Gates V, Abecassis MM, Omary RA, Baker TB, Salem R. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16:1587-1596. [PMID: 19357924 DOI: 10.1245/s10434-009-0454-0] [Cited by in Crossref: 134] [Cited by in F6Publishing: 125] [Article Influence: 10.3] [Reference Citation Analysis]
88 Yoon J, Lee S, Shin J, Kim SS, Kim GM, Won JY. LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma. Korean J Radiol 2021;22:1279-88. [PMID: 33987991 DOI: 10.3348/kjr.2020.1159] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Lee JS, Choi HJ, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baek SE, Chung YE, Park MS, Kim MJ, Rhee H, Kim SU. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. Gut Liver 2020;14:765-74. [PMID: 32050313 DOI: 10.5009/gnl19197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
90 Braat AJ, Smits ML, Braat MN, van den Hoven AF, Prince JF, de Jong HW, van den Bosch MA, Lam MG. ⁹⁰Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments. J Nucl Med 2015;56:1079-87. [PMID: 25952741 DOI: 10.2967/jnumed.115.157446] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
91 Kishore S, Friedman T, Madoff DC. Update on Embolization Therapies for Hepatocellular Carcinoma. Curr Oncol Rep 2017;19:40. [PMID: 28421483 DOI: 10.1007/s11912-017-0597-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
92 Birgin E, Rasbach E, Seyfried S, Rathmann N, Diehl SJ, Schoenberg SO, Reissfelder C, Rahbari NN. Contralateral Liver Hypertrophy and Oncological Outcome Following Radioembolization with 90Y-Microspheres: A Systematic Review. Cancers (Basel). 2020;12. [PMID: 32012709 DOI: 10.3390/cancers12020294] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
93 Klimkowski S, Baker JC, Brown DB. Red Flags, Pitfalls, and Cautions in Y90 Radiotherapy. Tech Vasc Interv Radiol 2019;22:63-9. [PMID: 31079712 DOI: 10.1053/j.tvir.2019.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Riaz A, Lewandowski RJ, Salem R. Locoregional Therapies for Primary and Secondary Hepatic Malignancies. In: Bentrem D, Benson AB, editors. Gastrointestinal Malignancies. Cham: Springer International Publishing; 2016. pp. 233-56. [DOI: 10.1007/978-3-319-34244-3_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
95 Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M. Clinical studies in hepatocellular carcinoma. Future Oncol 2014;10:13-6. [PMID: 25478761 DOI: 10.2217/fon.14.217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
96 Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular Carcinoma: Current Management and Perspectives for the Future. Annals of Surgery 2011;253:453-69. [DOI: 10.1097/sla.0b013e31820d944f] [Cited by in Crossref: 282] [Cited by in F6Publishing: 170] [Article Influence: 25.6] [Reference Citation Analysis]
97 Sangro B. Chemoembolization and radioembolization. Best Practice & Research Clinical Gastroenterology 2014;28:909-19. [DOI: 10.1016/j.bpg.2014.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
98 Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol 2015; 21(12): 3462-3471 [PMID: 25834310 DOI: 10.3748/wjg.v21.i12.3462] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
99 Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52:1741-9. [DOI: 10.1002/hep.23944] [Cited by in Crossref: 267] [Cited by in F6Publishing: 245] [Article Influence: 22.3] [Reference Citation Analysis]
100 Taussig MD, Irene Koran ME, Mouli SK, Ahmad A, Geevarghese S, Baker JC, Lipnik AJ, Banovac F, Brown DB. Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma. HPB 2017;19:458-64. [DOI: 10.1016/j.hpb.2017.01.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
101 Li H, Chen L, Zhu GY, Yao X, Dong R, Guo JH. Interventional Treatment for Cholangiocarcinoma. Front Oncol 2021;11:671327. [PMID: 34268114 DOI: 10.3389/fonc.2021.671327] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol 2015; 7(20): 2274-2291 [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
103 Chai NX, Chapiro J. Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice. Semin Intervent Radiol 2020;37:456-65. [PMID: 33328701 DOI: 10.1055/s-0040-1719186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015;7:738-52. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Reference Citation Analysis]
105 Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116:1305-1314. [PMID: 20066715 DOI: 10.1002/cncr.24884] [Cited by in Crossref: 120] [Cited by in F6Publishing: 116] [Article Influence: 10.0] [Reference Citation Analysis]
106 Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Ann Gastroenterol 2018;31:315-29. [PMID: 29720857 DOI: 10.20524/aog.2018.0245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
107 Lee IJ, Seong J. The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver 2012;6:139-48. [PMID: 22570744 DOI: 10.5009/gnl.2012.6.2.139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
108 Bryce K, Tsochatzis EA. Downstaging for hepatocellular cancer: harm or benefit? Transl Gastroenterol Hepatol. 2017;2:106. [PMID: 29354763 DOI: 10.21037/tgh.2017.11.18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
109 Lobo L, Yakoub D, Picado O, Ripat C, Pendola F, Sharma R, ElTawil R, Kwon D, Venkat S, Portelance L, Yechieli R. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol. 2016;39:1580-1588. [PMID: 27586657 DOI: 10.1007/s00270-016-1426-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 8.3] [Reference Citation Analysis]
110 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-S37. [PMID: 18304676 DOI: 10.1016/j.jhep.2008.01.022] [Cited by in Crossref: 576] [Cited by in F6Publishing: 571] [Article Influence: 41.1] [Reference Citation Analysis]
111 Teo JY, Goh BK. Contra-lateral liver lobe hypertrophy after unilobar Y90 radioembolization: An alternative to portal vein embolization? World J Gastroenterol 2015; 21(11): 3170-3173 [PMID: 25805922 DOI: 10.3748/wjg.v21.i11.3170] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
112 Kis B, El-Haddad G, Sheth RA, Parikh NS, Ganguli S, Shyn PB, Choi J, Brown KT. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729244. [PMID: 28975829 DOI: 10.1177/1073274817729244] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
113 Zhang ZF, Luo YJ, Lu Q, Dai SX, Sha WH. Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new? World J Clin Cases 2018; 6(9): 259-273 [PMID: 30211206 DOI: 10.12998/wjcc.v6.i9.259] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
114 Radeleff B, Stampfl U, Sommer C, Bellemann N, Hoffmann K, Ganten T, Ehehalt R, Kauczor H. Transvaskuläre Ablation des hepatozellulären Karzinoms: Ist Chemotherapie alles? Radiologe 2012;52:44-55. [DOI: 10.1007/s00117-011-2211-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
115 Patkar S, Parray A, Mahendra B, Kurunkar S, Goel M. Performance of Hong Kong Liver Cancer staging system in patients of hepatocellular carcinoma treated with surgical resection: An Indian validation study. J Surg Oncol 2019;120:1119-25. [PMID: 31549392 DOI: 10.1002/jso.25704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Akkiz H, Carr BI, Kuran S, Karaoğullarından Ü, Üsküdar O, Tokmak S, Arslan B, Doran F, Balli HT, Ülkü A, Akçam TA, Bahçeci Hİ, Polat KY, Örmeci N, Şimşek H, Sonsuz A, Demir A, Altıntaş E, Demir M, Yalçın K, Ekinci N, Harmancı Özakyol A, Yücesoy M, Uygun A, Guerra V, Delik A, Tokat Y, Yilmaz S, Bektaş A, Kılıç M. Macroscopic Portal Vein Thrombosis in HCC Patients. Can J Gastroenterol Hepatol. 2018;2018:3120185. [PMID: 30009156 DOI: 10.1155/2018/3120185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
117 Granito A, Bolondi L. Medical treatment of hepatocellular carcinoma. Mediterr J Hematol Infect Dis 2009;1:e2009021. [PMID: 21415957 DOI: 10.4084/MJHID.2009.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Volkan-Salancı B, Bozkurt MF, Peynircioğlu B, Cil B, Uğur O. The relation between perfusion pattern of hepatic artery perfusion scintigraphy and response to y-90 microsphere therapy. Mol Imaging Radionucl Ther 2013;22:98-102. [PMID: 24416626 DOI: 10.4274/Mirt.77487] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
119 Lee EW, Alanis L, Cho SK, Saab S. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. Korean J Radiol. 2016;17:472-488. [PMID: 27390539 DOI: 10.3348/kjr.2016.17.4.472] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
120 Likhitsup A, Razumilava N, Parikh ND. Treatment for Advanced Hepatocellular Carcinoma: Current Standard and the Future. Clin Liver Dis (Hoboken) 2019;13:13-9. [PMID: 31168360 DOI: 10.1002/cld.782] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
121 Mora RA, Ali R, Gabr A, Abouchaleh N, Asadi AA, Kallini JR, Miller FH, Yaghmai V, Mouli S, Thornburg B, Desai K, Riaz A, Lewandowski RJ, Salem R. Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma. Abdom Radiol 2018;43:1723-38. [DOI: 10.1007/s00261-017-1391-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
122 Oehme L, Kotzerke J. Radiobiological considerations for radioembolization with 188Re-microspheres. Eur J Nucl Med Mol Imaging 2009;36:322-5. [PMID: 19018527 DOI: 10.1007/s00259-008-0991-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
123 Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, Gansen DN, de Groen PC, Lazaridis KN, Narayanan Menon KV, Larusso NF, Alberts SR, Gores GJ, Fleming CJ, Slettedahl SW, Harmsen WS, Therneau TM, Wiseman GA, Andrews JC, Roberts LR. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013;36:714-723. [PMID: 23093355 DOI: 10.1007/s00270-012-0481-2] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 8.2] [Reference Citation Analysis]
124 Kan RW, Tsang SH, Poon RT, Cheung TT. Update on yttrium-90-based radio-embolization for treatment of hepatocellular carcinoma. ANZ J Surg. 2012;82:505-509. [PMID: 22747591 DOI: 10.1111/j.1445-2197.2012.06121.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
125 Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B. Imaging Assessment of Hepatocellular Carcinoma Response to Locoregional and Systemic Therapy. American Journal of Roentgenology 2013;201:80-96. [DOI: 10.2214/ajr.13.10706] [Cited by in Crossref: 53] [Cited by in F6Publishing: 18] [Article Influence: 5.9] [Reference Citation Analysis]
126 Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, Omary RA, Salem R. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol. 2009;20:1121-30; quiz 1131. [PMID: 19640737 DOI: 10.1016/j.jvir.2009.05.030] [Cited by in Crossref: 226] [Cited by in F6Publishing: 192] [Article Influence: 17.4] [Reference Citation Analysis]
127 Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, Goh AS, Yan SX, Loke KS, Thang SP, Gogna A, Too CW, Irani FG, Leong S, Lim KH, Thng CH. National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. Liver Cancer. 2016;5:97-106. [PMID: 27386428 DOI: 10.1159/000367759] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
128 Teo JY, Goh BK, Cheah FK, Allen JC, Lo RH, Ng DC, Goh AS, Khor AY, Sim HS, Ng JJ. Underlying liver disease influences volumetric changes in the spared hemiliver after selective internal radiation therapy with 90Y in patients with hepatocellular carcinoma. J Dig Dis. 2014;15:444-450. [PMID: 24828952 DOI: 10.1111/1751-2980.12162] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
129 Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E. Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer 2019;8:281-94. [PMID: 31602371 DOI: 10.1159/000490260] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
130 Biederman DM, Titano JJ, Tabori NE, Pierobon ES, Alshebeeb K, Schwartz M, Facciuto ME, Gunasekaran G, Florman S, Fischman AM, Patel RS, Nowakowski FS, Kim E. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres. Journal of Vascular and Interventional Radiology 2016;27:812-821.e2. [DOI: 10.1016/j.jvir.2016.01.147] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
131 Abi-jaoudeh N. Resin versus Glass Microspheres. Journal of Vascular and Interventional Radiology 2016;27:822-3. [DOI: 10.1016/j.jvir.2016.02.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
132 Chino F, Stephens SJ, Choi SS, Marin D, Kim CY, Morse MA, Godfrey DJ, Czito BG, Willett CG, Palta M. The role of external beam radiotherapy in the treatment of hepatocellular cancer. Cancer. 2018;124:3476-3489. [PMID: 29645076 DOI: 10.1002/cncr.31334] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
133 Yang TX, Chua TC, Morris DL. Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases - a systematic review. Surg Oncol 2012;21:299-308. [PMID: 22846894 DOI: 10.1016/j.suronc.2012.07.001] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
134 Hruby M, Skodova M, Mackova H, Skopal J, Tomes M, Kropacek M, Zimova J, Kucka J. Lutetium-177 and iodine-131 loaded chelating polymer microparticles intended for radioembolization of liver malignancies. Reactive and Functional Polymers 2011;71:1155-9. [DOI: 10.1016/j.reactfunctpolym.2011.09.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
135 Kishi Y, Shimada K, Nara S, Esaki M, Kosuge T. Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma. World J Hepatol 2014; 6(12): 836-843 [PMID: 25544870 DOI: 10.4254/wjh.v6.i12.836] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
136 Crocetti L, Della Pina C, Cioni D, Lencioni R. Peri-intraprocedural imaging: US, CT, and MRI. Abdom Imaging 2011;36:648-60. [DOI: 10.1007/s00261-011-9750-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
137 Lawhn-heath C, Hope TA, Martinez J, Fung EK, Shin J, Seo Y, Flavell RR. Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. The Lancet Oncology 2022;23:e75-87. [DOI: 10.1016/s1470-2045(21)00657-4] [Reference Citation Analysis]
138 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol 2013;19:7316-26. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
139 Marrero JA, Welling T. Modern Diagnosis and Management of Hepatocellular Carcinoma. Clinics in Liver Disease 2009;13:233-47. [DOI: 10.1016/j.cld.2009.02.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
140 Wáng YX, De Baere T, Idée JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015;27:96-121. [PMID: 25937772 DOI: 10.3978/j.issn.1000-9604.2015.03.03] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
141 Choi JW, Kim H, Lee J, Yu SJ, Kim YJ, Yoon J, Jae HJ, Hur S, Lee M, Chung JW. Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. Eur Radiol 2017;27:1448-58. [DOI: 10.1007/s00330-016-4511-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
142 Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiotherapy and Oncology 2018;129:112-22. [DOI: 10.1016/j.radonc.2017.11.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
143 Song JE, Jung KS, Kim DY, Song K, Won JY, Lee HW, Kim BK, Kim SU, Park JY, Ahn SH, Seong J, Han KH. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Int J Radiat Oncol Biol Phys 2017;99:396-406. [PMID: 28871990 DOI: 10.1016/j.ijrobp.2017.05.049] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
144 Minocha J, Salem R, Lewandowski RJ. Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions. Clin Liver Dis. 2014;18:877-890. [PMID: 25438288 DOI: 10.1016/j.cld.2014.07.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
145 Meza-Junco J, Montano-Loza AJ, Liu DM, Sawyer MB, Bain VG, Ma M, Owen R. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev 2012;38:54-62. [PMID: 21726960 DOI: 10.1016/j.ctrv.2011.05.002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
146 Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, Chan SL, Cheung MT, Lai TW, Cheung CC. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer. 2015;4:51-69. [PMID: 26020029 DOI: 10.1159/000367728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
147 Bauschke A, Altendorf-Hofmann A, Ardelt M, Kissler H, Tautenhahn HM, Settmacher U. Impact of successful local ablative bridging therapy prior to liver transplantation on long-term survival in patients with hepatocellular carcinoma in cirrhosis. J Cancer Res Clin Oncol 2020;146:1819-27. [PMID: 32356179 DOI: 10.1007/s00432-020-03215-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
148 Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. Journal of Hepatology 2012;56:464-73. [DOI: 10.1016/j.jhep.2011.07.012] [Cited by in Crossref: 173] [Cited by in F6Publishing: 175] [Article Influence: 17.3] [Reference Citation Analysis]
149 Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013;58:2188-97. [PMID: 23512791 DOI: 10.1002/hep.26382] [Cited by in Crossref: 109] [Cited by in F6Publishing: 110] [Article Influence: 12.1] [Reference Citation Analysis]
150 Titano J, Noor A, Kim E. Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages. Semin Intervent Radiol 2017;34:109-15. [PMID: 28579678 DOI: 10.1055/s-0037-1602709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
151 Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. Jpn J Clin Oncol. 2012;42:247-255. [PMID: 22407946 DOI: 10.1093/jjco/hys020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
152 Luo J, Yan Z, Liu Q, Qu X, Wang J. Endovascular placement of iodine-125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein. J Vasc Interv Radiol. 2011;22:479-489. [PMID: 21463757 DOI: 10.1016/j.jvir.2010.11.029] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
153 Kwok PC, Leung KC, Cheung MT, Lam TW, Szeto LT, Chou SQ, Chia NH, Tong CM, Yuen PK, Cheung CH, Law CK. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres. J Gastroenterol Hepatol 2014;29:1897-904. [PMID: 24734957 DOI: 10.1111/jgh.12621] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
154 Teo JY, Allen JC Jr, Ng DC, Choo SP, Tai DW, Chang JP, Cheah FK, Chow PK, Goh BK. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. HPB (Oxford) 2015. [PMID: 26472490 DOI: 10.1111/hpb.12490] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
155 Sato KT. Yttrium-90 radioembolization for the treatment of primary and metastatic liver tumors. Semin Roentgenol. 2011;46:159-165. [PMID: 21338841 DOI: 10.1053/j.ro.2010.08.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
156 Oligane HC, Close ON, Xing M, Kim HS. Bridging locoregional therapy: Longitudinal trends and outcomes in patients with hepatocellular carcinoma. Transplant Rev (Orlando) 2017;31:136-43. [PMID: 28214240 DOI: 10.1016/j.trre.2017.01.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
157 Erinjeri JP, Fine GC, Adema GJ, Ahmed M, Chapiro J, den Brok M, Duran R, Hunt SJ, Johnson DT, Ricke J, Sze DY, Toskich BB, Wood BJ, Woodrum D, Goldberg SN. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper. Radiology 2019;292:25-34. [PMID: 31012818 DOI: 10.1148/radiol.2019182326] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
158 Bhoori S, Sposito C, Germini A, Coppa J, Mazzaferro V. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. Transpl Int. 2010;23:712-722. [PMID: 20492616 DOI: 10.1111/j.1432-2277.2010.01111.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
159 Tong YS, Cao XF. Brachytherapy with iodine-125 seeds for hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2013; 21(29): 3072-3077 [DOI: 10.11569/wcjd.v21.i29.3072] [Reference Citation Analysis]
160 Nazzal M, Gadani S, Said A, Rice M, Okoye O, Taha A, Lentine K. Liver targeted therapies for hepatocellular carcinoma prior to transplant: contemporary management strategies. Glob Surg 2017;3. [DOI: 10.15761/gos.1000171] [Reference Citation Analysis]
161 Aguado A, Dunn SP, Averill LW, Chikwava KR, Gresh R, Rabinowitz D, Katzenstein HM. Successful use of transarterial radioembolization with yttrium-90 (TARE-Y90) in two children with hepatoblastoma. Pediatr Blood Cancer 2020;67:e28421. [PMID: 32603027 DOI: 10.1002/pbc.28421] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
162 Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol. 2015;88:20140564. [PMID: 25978585 DOI: 10.1259/bjr.20140564] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
163 Vilarinho S, Taddei T. Therapeutic strategies for hepatocellular carcinoma: new advances and challenges. Curr Treat Options Gastroenterol 2015;13:219-34. [PMID: 25791207 DOI: 10.1007/s11938-015-0049-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
164 Crocetti L, Bargellini I, Cioni R. Loco-regional treatment of HCC: current status. Clin Radiol. 2017;72:626-635. [PMID: 28258743 DOI: 10.1016/j.crad.2017.01.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
165 Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Ibrahim S, Mulcahy MF, Kulik L. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31:431-438. [PMID: 18838878 DOI: 10.1097/coc.0b013e318168ef65] [Cited by in Crossref: 105] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
166 Chaikajornwat J, Tanasoontrarat W, Phathong C, Pinjaroen N, Chaiteerakij R. Clinical outcome of Yttrium-90 selective internal radiation therapy (Y-90 SIRT) in unresectable hepatocellular carcinoma: Experience from a tertiary care center. Liver Research 2021. [DOI: 10.1016/j.livres.2021.07.001] [Reference Citation Analysis]
167 Riaz A, Kulik LM, Mulcahy MF, Lewandowski RJ, Salem R. Yttrium-90 radioembolization in the management of liver malignancies. Semin Oncol. 2010;37:94-101. [PMID: 20494701 DOI: 10.1053/j.seminoncol.2010.03.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
168 Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:123-133. [PMID: 22212946 DOI: 10.1159/000333275] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
169 Hamaoka M, Kobayashi T, Kuroda S, Iwako H, Okimoto S, Kimura T, Aikata H, Nagata Y, Chayama K, Ohdan H. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study. International Journal of Surgery 2017;44:223-8. [DOI: 10.1016/j.ijsu.2017.06.082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
170 Pracht M, Edeline J, Lenoir L, Latournerie M, Mesbah H, Audrain O, Rolland Y, Clément B, Raoul JL, Garin E. Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: preliminary results. Int J Hepatol. 2013;2013:827649. [PMID: 23476792 DOI: 10.1155/2013/827649] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
171 Sotiropoulos G, Hilgard P, Antoch G, Nowak K, Ertl J, Fouzas I, Molmenti E, Sgourakis G, Beckebaum S, Paul A, Broelsch C, Lang H. Liver Transplantation for Hepatocellular Carcinoma After Yttrium Therapy: A Case Report. Transplantation Proceedings 2008;40:3804-5. [DOI: 10.1016/j.transproceed.2008.09.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
172 Iñarrairaegui M, Pardo F, Sangro B. Downstaging to liver resection by radioembolization: a difficult to reach strategy? Author reply. Eur J Surg Oncol 2013;39:920-1. [PMID: 23707136 DOI: 10.1016/j.ejso.2013.05.006] [Reference Citation Analysis]
173 Xiang X, Lau W, Wu Z, Zhao C, Ma Y, Xiang B, Zhu J, Zhong J, Li L. Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus:a multicenter study. European Journal of Surgical Oncology 2019;45:1460-7. [DOI: 10.1016/j.ejso.2019.03.042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
174 Zhong J, Zhong Q, Li L, Li H. Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review. Tumor Biol 2014;35:9459-68. [DOI: 10.1007/s13277-014-2443-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
175 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015; 7(5): 738-752 [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
176 Zang L, Luan C, Tang X, Lu J, Zhao Y. A simple low-molecular-mass organic gelator based on salicylaldehyde acylhydrazone: Gelation behavior and selective fluorescence sensing of Y3+. Dyes and Pigments 2021;196:109751. [DOI: 10.1016/j.dyepig.2021.109751] [Reference Citation Analysis]
177 Lau WY, Teoh YL, Win KM, Lee RC, de Villa VH, Kim YH, Liang PC, Santos-Ocampo RS, Lo RH, Lim KB, Tai DW, Ng DC, Irani FG, Gogna A, Chow PK. Current role of selective internal radiation with yttrium-90 in liver tumors. Future Oncol 2016;12:1193-204. [PMID: 27007495 DOI: 10.2217/fon-2016-0035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
178 Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Senthilnathan S, Baker T, Gates VL, Abecassis M, Benson AB 3rd, Mulcahy MF, Omary RA, Salem R. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141:526-35, 535.e1-2. [PMID: 21664356 DOI: 10.1053/j.gastro.2011.04.054] [Cited by in Crossref: 117] [Cited by in F6Publishing: 108] [Article Influence: 10.6] [Reference Citation Analysis]
179 Kim HC, Chung JW, Park JH, An S, Son KR, Seong NJ, Jae HJ. Transcatheter arterial chemoembolization for hepatocellular carcinoma: prospective assessment of the right inferior phrenic artery with C-arm CT. J Vasc Interv Radiol 2009;20:888-95. [PMID: 19481471 DOI: 10.1016/j.jvir.2009.03.036] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
180 Takayasu K. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective. Oncology. 2013;84 Suppl 1:28-33. [PMID: 23428855 DOI: 10.1159/000345886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
181 Zarrinpar A, Kaldas F, Busuttil RW. Liver transplantation for hepatocellular carcinoma: an update. Hepatobiliary & Pancreatic Diseases International 2011;10:234-42. [DOI: 10.1016/s1499-3872(11)60039-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
182 Kallini JR, Gabr A, Thorlund K, Balijepalli C, Ayres D, Kanters S, Ebrahim S, Mills E, Lewandowski RJ, Salem R. Comparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review. Cardiovasc Intervent Radiol 2017;40:1033-43. [DOI: 10.1007/s00270-017-1594-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
183 Gates VL, Salem R, Lewandowski RJ. Positron Emission Tomography/CT after Yttrium-90 Radioembolization: Current and Future Applications. Journal of Vascular and Interventional Radiology 2013;24:1153-5. [DOI: 10.1016/j.jvir.2013.06.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
184 Shamimi-Noori S, Gonsalves CF, Shaw CM. Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data.Semin Intervent Radiol. 2017;34:145-166. [PMID: 28579683 DOI: 10.1055/s-0037-1602712] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
185 Sutter O, Calvo J, N'Kontchou G, Nault JC, Ourabia R, Nahon P, Ganne-Carrié N, Bourcier V, Zentar N, Bouhafs F, Sellier N, Diallo A, Seror O. Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series. Radiology 2017;284:877-86. [PMID: 28453431 DOI: 10.1148/radiol.2017161413] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
186 Lewandowski RJ, Riaz A, Ryu RK, Mulcahy MF, Sato KT, Kulik LM, Gates VL, Baker T, Omary R, Salem R. Optimization of Radioembolic Effect with Extended-shelf-life Yttrium-90 Microspheres: Results from a Pilot Study. Journal of Vascular and Interventional Radiology 2009;20:1557-63. [DOI: 10.1016/j.jvir.2009.08.021] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
187 Yang M, Fang Z, Yan Z, Luo J, Liu L, Zhang W, Wu L, Ma J, Yang Q, Liu Q. Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial. J Cancer Res Clin Oncol. 2014;140:211-219. [PMID: 24374800 DOI: 10.1007/s00432-013-1568-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
188 Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, Makuuchi M; Liver Cancer Study Group of Japan. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 2010;194:830-7. [PMID: 20173167 DOI: 10.2214/AJR.09.3308] [Cited by in Crossref: 70] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
189 Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010;12:313-320. [PMID: 20590905 DOI: 10.1111/j.1477-2574.2010.00183.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
190 Quick AM, Lo SS, Mayr NA, Kim EY. Radiation therapy for intrahepatic malignancies. Expert Review of Anticancer Therapy 2014;9:1511-21. [DOI: 10.1586/era.09.114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
191 Xu G, Jin B, Xian X, Yang H, Zhao H, Du S, Makuuchi M, Pawlik TM, Mao Y. Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer 2021;10:137-50. [PMID: 33977090 DOI: 10.1159/000513412] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
192 Fartoux L, Rosmorduc O. Evidence-based integration of selective internal radiation therapy into the management of cholangiocarcinoma. Future Oncol 2014;10:89-92. [PMID: 25478776 DOI: 10.2217/fon.14.232] [Reference Citation Analysis]
193 Teo JY, Allen JC, Ng DCE, Abdul Latiff JB, Choo SP, Tai DW, Low ASC, Cheah FK, Chang JPE, Kam JH, Lee VTW, Chung AYF, Chan CY, Chow PKH, Goh BKP. Prospective study to determine early hypertrophy of the contra-lateral liver lobe after unilobar, Yttrium-90, selective internal radiation therapy in patients with hepatocellular carcinoma. Surgery 2018;163:1008-13. [PMID: 29306542 DOI: 10.1016/j.surg.2017.10.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
194 Borgheresi A, Covey A, Yarmohammadi H, Boas FE, Ziv E, Getrajdman G, Erinjeri J, Jarnagin W, Harding JJ, D'Angelica M, Gonen M, Brown KT. Embolization with microspheres alone for hepatocellular carcinoma with portal vein tumor: analysis of outcome and liver function at disease progression. HPB (Oxford) 2020;22:588-94. [PMID: 31474455 DOI: 10.1016/j.hpb.2019.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
195 Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J. 2010;16:163-175. [PMID: 20404614 DOI: 10.1097/ppo.0b013e3181d7e8cf] [Cited by in Crossref: 61] [Cited by in F6Publishing: 28] [Article Influence: 5.1] [Reference Citation Analysis]
196 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
197 Wong R, Frenette C, Gish R. Hepatocellular carcinoma: locoregional and targeted therapies. Gastroenterol Clin North Am. 2011;40:599-610. [PMID: 21893276 DOI: 10.1016/j.gtc.2011.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
198 McDevitt JL, Alian A, Kapoor B, Bennett S, Gill A, Levitin A, Sands M, Narayanan Menon KV, Aucejo FN, Estfan B, Pillai AK, Kalva SP, McLennan G. Single-Center Comparison of Overall Survival and Toxicities in Patients with Infiltrative Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization or Drug-Eluting Embolic Transarterial Chemoembolization. J Vasc Interv Radiol 2017;28:1371-7. [PMID: 28689934 DOI: 10.1016/j.jvir.2017.05.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
199 Andreana L, Isgrò G, Marelli L, Davies N, Yu D, Navalkissoor S, Burroughs AK. Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: trans-arterial radio-embolisation of HCC. Cancer Treat Rev. 2012;38:641-649. [PMID: 22169503 DOI: 10.1016/j.ctrv.2011.11.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
200 Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, Abecassis M, Baker T, Gates V, Nayar R, Miller FH, Sato KT, Omary RA, Salem R. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology. 2009;49:1185-1193. [PMID: 19133645 DOI: 10.1002/hep.22747] [Cited by in Crossref: 185] [Cited by in F6Publishing: 162] [Article Influence: 14.2] [Reference Citation Analysis]
201 Li W, Wang Y, Gao W, Zheng J. Combination of transcatheter arterial chemoembolization and CT-guided percutaneous segment ablation for hepatocellular carcinoma therapy: A retrospective study. Medicine (Baltimore) 2016;95:e5422. [PMID: 27893681 DOI: 10.1097/MD.0000000000005422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
202 Waneck F. [Targeted radiological therapy of liver tumors]. Radiologe 2015;55:43-7. [PMID: 25609580 DOI: 10.1007/s00117-014-2707-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
203 Padia SA, Alessio A, Kwan SW, Lewis DH, Vaidya S, Minoshima S. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis. J Vasc Interv Radiol 2013;24:1147-53. [PMID: 23792126 DOI: 10.1016/j.jvir.2013.04.018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
204 Floridi C, Pesapane F, Angileri SA, De Palma D, Fontana F, Caspani F, Barile A, Del Sole A, Masciocchi C, Lucignani G, Carrafiello G. Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis. Med Oncol 2017;34. [DOI: 10.1007/s12032-017-1021-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
205 Wörns MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S302-S309. [PMID: 20547319 DOI: 10.1016/S1590-8658(10)60521-X] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
206 Walcott-Sapp S, Naugler S, Lim JY, Wagner J, Orloff SL, Farsad K, Kolbeck KJ, Kaufman J, Maynard E, Enestvedt CK, Mayo SC, Billingsley KG. Tailored treatment of patients with hepatocellular carcinoma with portal vein invasion: experience from a multidisciplinary hepatobiliary tumor program within a NCI comprehensive cancer center. J Gastrointest Oncol 2018;9:1074-83. [PMID: 30603126 DOI: 10.21037/jgo.2018.08.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
207 Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol 2015; 7(3): 566-574 [PMID: 25848480 DOI: 10.4254/wjh.v7.i3.566] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
208 Marqueen KE, Kim E, Ang C, Mazumdar M, Buckstein M, Ferket BS. Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma. JCO Oncol Pract 2021;17:e266-77. [PMID: 33417490 DOI: 10.1200/OP.20.00443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
209 D'Avola D, Iñarrairaegui M, Pardo F, Rotellar F, Marti P, Bilbao JI, Martinez-Cuesta A, Benito A, Alegre F, Mauleón E, Herrero JI, Quiroga J, Prieto J, Sangro B. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. Ann Surg Oncol 2011;18:1964-71. [PMID: 21267791 DOI: 10.1245/s10434-011-1551-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
210 Kim Y, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization. Curr Oncol 2021;28:965-77. [PMID: 33617513 DOI: 10.3390/curroncol28010095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Dufour JF, Johnson P. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. J Hepatol 2010;52:296-304. [PMID: 20006399 DOI: 10.1016/j.jhep.2009.11.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
212 Sanoff HK, Chang Y, Stavas JM, Stürmer T, Lund J. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries. J Natl Compr Canc Netw 2015;13:1102-10. [PMID: 26358794 DOI: 10.6004/jnccn.2015.0135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
213 Helmberger T, Golfieri R, Pech M, Pfammatter T, Arnold D, Cianni R, Maleux G, Munneke G, Pellerin O, Peynircioglu B, Sangro B, Schaefer N, de Jong N, Bilbao JI; On behalf of the CIRT Steering Committee., On behalf of the CIRT Principal Investigators. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT). Cardiovasc Intervent Radiol 2021;44:21-35. [PMID: 32959085 DOI: 10.1007/s00270-020-02642-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
214 Lewandowski RJ, Minocha J, Memon K, Riaz A, Gates VL, Ryu RK, Sato KT, Omary R, Salem R. Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort. Eur J Nucl Med Mol Imaging 2014;41:486-93. [DOI: 10.1007/s00259-013-2575-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
215 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
216 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
217 Sacco R, Mismas V, Marceglia S, Romano A, Giacomelli L, Bertini M, Federici G, Metrangolo S, Parisi G, Tumino E, Bresci G, Corti A, Tredici M, Piccinno M, Giorgi L, Bartolozzi C, Bargellini I. Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives. World J Gastroenterol 2015; 21(21): 6518-6525 [PMID: 26074690 DOI: 10.3748/wjg.v21.i21.6518] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
218 Bozkurt MF, Salanci BV, Uğur Ö. Intra-Arterial Radionuclide Therapies for Liver Tumors. Seminars in Nuclear Medicine 2016;46:324-39. [DOI: 10.1053/j.semnuclmed.2016.01.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
219 Shen ZT, Chen Y, Huang GC, Zhu XX, Wang R, Chen LB. Aurora-a confers radioresistance in human hepatocellular carcinoma by activating NF-κB signaling pathway. BMC Cancer 2019;19:1075. [PMID: 31703572 DOI: 10.1186/s12885-019-6312-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
220 Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734-5742. [PMID: 19805671 DOI: 10.1200/jco.2009.23.1282] [Cited by in Crossref: 155] [Cited by in F6Publishing: 73] [Article Influence: 11.9] [Reference Citation Analysis]
221 Memon K, Lewandowski RJ, Riaz A, Salem R. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:207-224. [PMID: 22941023 DOI: 10.1007/978-3-642-16037-0_14] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
222 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 256] [Article Influence: 69.7] [Reference Citation Analysis]
223 Forner A, Rodríguez De Lope C, Reig M, Bruix J. [Treatment of advanced hepatocellular carcinoma]. Gastroenterol Hepatol 2010;33:461-8. [PMID: 20227796 DOI: 10.1016/j.gastrohep.2009.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
224 Akinwande O, Kim D, Edwards J, Brown R, Philips P, Scoggins C, Martin RC 2nd. Is radioembolization ((90)Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis. Surg Oncol. 2015;24:270-275. [PMID: 26133576 DOI: 10.1016/j.suronc.2015.06.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
225 Pan T, Li XS, Xie QK, Wang JP, Li W, Wu PH, Zhao M. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. Clin Radiol. 2014;69:e553-e561. [PMID: 25304928 DOI: 10.1016/j.crad.2014.09.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
226 Hetta OM, Hetta WM, Shebrya NH, El Ghazaly HA. Radioembolization with Yttrium-90 resin microspheres in treatment of HCC with or without PVT: Initial Egyptian experience. The Egyptian Journal of Radiology and Nuclear Medicine 2013;44:215-22. [DOI: 10.1016/j.ejrnm.2013.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
227 Wallace MC, Samuelson S, Khoo T, Ooi J, Tibballs J, Ferguson J, Preen DB, Knuiman M, Garas G, MacQuillan G, Adams LA, Jeffrey GP. The MAAPE score in intermediate and advanced hepatocellular carcinoma treated with Yttrium-90 resin microsphere radioembolization. J Gastroenterol Hepatol 2020;35:1945-52. [PMID: 32036614 DOI: 10.1111/jgh.15008] [Reference Citation Analysis]
228 Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2. [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049] [Cited by in Crossref: 390] [Cited by in F6Publishing: 366] [Article Influence: 32.5] [Reference Citation Analysis]
229 Shi Y, Zhai B. A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma. Gastrointest Tumors 2016;3:90-102. [PMID: 27904861 DOI: 10.1159/000445888] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
230 Sangro B, D'avola D, Iñarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2011;12:1057-73. [DOI: 10.1517/14656566.2011.545346] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
231 Raoul JL, Boucher E, Rolland Y, Garin E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat Rev Gastroenterol Hepatol 2010;7:41-9. [PMID: 20051971 DOI: 10.1038/nrgastro.2009.202] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
232 II JDR, McDonald AM, Baden CJ, Lin CP, Jacob R, III OLB. Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignancies. World J Gastroenterol 2016; 22(10): 3006-3014 [PMID: 26973396 DOI: 10.3748/wjg.v22.i10.3006] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
233 Woodall CE, Scoggins CR, Ellis SF, Tatum CM, Hahl MJ, Ravindra KV, McMasters KM, Martin RC. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg. 2009;208:375-382. [PMID: 19317999 DOI: 10.1016/j.jamcollsurg.2008.12.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 50] [Article Influence: 3.2] [Reference Citation Analysis]
234 Bester L, Meteling B, Boshell D, Chua TC, Morris DL. Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: A review of the literature: Embolisation therapies in liver cancer. Journal of Medical Imaging and Radiation Oncology 2014;58:341-52. [DOI: 10.1111/1754-9485.12163] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
235 Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol 2016;89:20150943. [PMID: 26943239 DOI: 10.1259/bjr.20150943] [Cited by in Crossref: 47] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
236 Reig M, da Fonseca LG, Faivre S. New trials and results in systemic treatment of HCC. J Hepatol 2018;69:525-33. [PMID: 29653122 DOI: 10.1016/j.jhep.2018.03.028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 7.3] [Reference Citation Analysis]
237 Burak KW, Thomas MB, Zhu AX. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference. HPB (Oxford) 2010;12:321-2. [PMID: 20590906 DOI: 10.1111/j.1477-2574.2010.00186.x] [Reference Citation Analysis]
238 Teyateeti A, Mahvash A, Long J, Abdelsalam M, Avritscher R, Kaseb A, Odisio B, Ravizzini G, Surasi D, Teyateeti A, Macapinlac H, Kappadath SC. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol 2021; 27(47): 8166-8181 [DOI: 10.3748/wjg.v27.i47.8166] [Reference Citation Analysis]
239 Abouchaleh N, Gabr A, Ali R, Al Asadi A, Mora RA, Kallini JR, Mouli S, Riaz A, Lewandowski RJ, Salem R. 90 Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort. J Nucl Med 2018;59:1042-8. [DOI: 10.2967/jnumed.117.199752] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
240 Wörns MA, Klöckner R, Weinmann A, Galle PR. [Therapy of hepatocellular carcinoma]. Internist (Berl). 2014;55:23-24, 26-30. [PMID: 24240604 DOI: 10.1007/s00108-013-3318-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
241 Tarantino L, Busto G, Nasto A, Fristachi R, Cacace L, Talamo M, Accardo C, Bortone S, Gallo P, Tarantino P, Nasto RA, Di Minno MND, Ambrosino P. Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study. World J Gastroenterol 2017; 23(5): 906-918 [PMID: 28223736 DOI: 10.3748/wjg.v23.i5.906] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
242 Malek NP, Vogel A, Manns MP. [Multimodality treatment for hepatocellular carcinoma]. Internist (Berl) 2010;51:1374-81. [PMID: 20938626 DOI: 10.1007/s00108-010-2673-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
243 Chung SR, Kim JH, Yoon HK, Ko GY, Gwon DI, Shin JH, Song HY, Ko HK, Yoon SM. Combined Cisplatin-Based Chemoembolization and Radiation Therapy for Hepatocellular Carcinoma Invading the Main Portal Vein. J Vasc Interv Radiol. 2015;26:1130-1138. [PMID: 26119202 DOI: 10.1016/j.jvir.2015.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
244 Lea WB, Tapp KN, Tann M, Hutchins GD, Fletcher JW, Johnson MS. Microsphere Localization and Dose Quantification Using Positron Emission Tomography/CT following Hepatic Intraarterial Radioembolization with Yttrium-90 in Patients with Advanced Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2014;25:1595-603. [DOI: 10.1016/j.jvir.2014.06.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
245 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
246 Padia SA, Chewning RH, Kogut MJ, Ingraham CR, Johnson GE, Bhattacharya R, Kwan SW, Monsky WL, Vaidya S, Hippe DS. Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts. Cardiovasc Intervent Radiol. 2015;38:913-921. [PMID: 25373795 DOI: 10.1007/s00270-014-1009-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
247 Rodríguez-Fraile M, Iñarrairaegui M. [Radioembolization with (90)Y-microspheres for liver tumors]. Rev Esp Med Nucl Imagen Mol 2015;34:244-57. [PMID: 25911062 DOI: 10.1016/j.remn.2015.03.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
248 Wang D, Gaba RC, Jin B, Lewandowski RJ, Riaz A, Memon K, Ryu RK, Sato KT, Kulik LM, Mulcahy MF, Larson AC, Salem R, Omary RA. Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma. Radiology 2014;272:587-97. [PMID: 24678859 DOI: 10.1148/radiol.14131311] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
249 Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, Newman SB, Benson A, Omary RA, Salem R. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113:2119-2128. [PMID: 18759346 DOI: 10.1002/cncr.23818] [Cited by in Crossref: 137] [Cited by in F6Publishing: 160] [Article Influence: 9.8] [Reference Citation Analysis]
250 Goffredo V, Paradiso A, Ranieri G, Gadaleta CD. Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). Crit Rev Oncol Hematol 2011;80:393-410. [PMID: 21388824 DOI: 10.1016/j.critrevonc.2011.01.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
251 Lüdemann W, Kahn J, Pustelnik D, Hardt J, Böning G, Jonczyk M, Amthauer H, Gebauer B, Hamm B, Wieners G. Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection. Eur Radiol 2022. [PMID: 35230518 DOI: 10.1007/s00330-022-08585-x] [Reference Citation Analysis]
252 Wang K, Lin B. Pathophysiological Significance of Hepatic Apoptosis. ISRN Hepatol 2013;2013:740149. [PMID: 27335822 DOI: 10.1155/2013/740149] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
253 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
254 Xie F, Zang J, Guo X, Xu F, Shen R, Yan L, Yang J, He J. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2012;138:455-62. [DOI: 10.1007/s00432-011-1117-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
255 Schumacher G, Gebauer B. Transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion: a helpful palliative approach. J Gastroenterol Hepatol 2009;24:1317-9. [PMID: 19702898 DOI: 10.1111/j.1440-1746.2009.05976.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
256 Carr BI, Guerra V. Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. Dig Dis Sci 2016;61:937-47. [PMID: 26576554 DOI: 10.1007/s10620-015-3922-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
257 Zhang XB, Wang JH, Yan ZP, Qian S, Du SS, Zeng ZC. Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. Cancer. 2009;115:1245-1252. [PMID: 19156918 DOI: 10.1002/cncr.24139] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
258 Gabr A, Entezari P, Riaz A, Salem R, Lewandowski RJ. Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma. Advances in Clinical Radiology 2020;2:113-25. [DOI: 10.1016/j.yacr.2020.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Carr BI. Review of therapies for intermediate and advanced stage hepatocellular carcinoma, not suitable for curative therapies: a rapidly changing landscape. Hepatoma Res 2019;5:3. [PMID: 30842979 DOI: 10.20517/2394-5079.2018.113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
260 Sangro B. Evidence-based integration of selective internal radiation therapy into hepatocellular carcinoma management. Future Oncol 2014;10:7-11. [PMID: 25478760 DOI: 10.2217/fon.14.216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
261 Bhangoo MS, Karnani DR, Hein PN, Giap H, Knowles H, Issa C, Steuterman S, Pockros P, Frenette C. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol 2015;6:469-78. [PMID: 26487939 DOI: 10.3978/j.issn.2078-6891.2015.056] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
262 Au JS, Frenette CT. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver. 2015;9:437-448. [PMID: 26087860 DOI: 10.5009/gnl15022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
263 Hickey RM, Lewandowski RJ, Salem R. Yttrium-90 Radioembolization for Hepatocellular Carcinoma. Seminars in Nuclear Medicine 2016;46:105-8. [DOI: 10.1053/j.semnuclmed.2015.10.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
264 Iñarrairaegui M, Martinez-Cuesta A, Rodríguez M, Bilbao JI, Arbizu J, Benito A, Alegre F, D'Avola D, Herrero JI, Quiroga J, Prieto J, Sangro B. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010;77:1441-8. [PMID: 20056355 DOI: 10.1016/j.ijrobp.2009.07.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
265 Meyer C, Pieper CC, Ahmadzadehfar H, Lampe NA, Matuschek EME, Maschke TA, Enkirch SJ, Essler M, Spengler U, Schild HH. Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience. Onco Targets Ther 2017;10:4773-85. [PMID: 29033589 DOI: 10.2147/OTT.S137519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
266 Kim GH, Kim JH, Kim PH, Chu HH, Gwon DI, Ko HK. Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Korean J Radiol 2021;22:1822-33. [PMID: 34431250 DOI: 10.3348/kjr.2021.0229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, Riaz A, Gupta R, Vouche M, Gates VL, Miller FH, Omary RA, Salem R. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol. 2013;58:73-80. [PMID: 23000237 DOI: 10.1016/j.jhep.2012.09.003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 7.9] [Reference Citation Analysis]
268 Abdelfattah MR, Al-Sebayel M, Broering D, Alsuhaibani H. Radioembolization using yttrium-90 microspheres as bridging and downstaging treatment for unresectable hepatocellular carcinoma before liver transplantation: initial single-center experience. Transplant Proc. 2015;47:408-411. [PMID: 25769582 DOI: 10.1016/j.transproceed.2014.11.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
269 Coldwell D, Sangro B, Wasan H, Salem R, Kennedy A. General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol. 2011;34:337-341. [PMID: 20921882 DOI: 10.1097/coc.0b013e3181ec61bb] [Cited by in Crossref: 54] [Cited by in F6Publishing: 18] [Article Influence: 4.9] [Reference Citation Analysis]
270 Hinrichs JB, Wacker FK. [Locoregional and local ablative treatment options for liver tumors]. Internist (Berl) 2020;61:158-63. [PMID: 31919532 DOI: 10.1007/s00108-019-00725-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
271 Piana PM, Gonsalves CF, Sato T, Anne PR, McCann JW, Bar Ad V, Eschelman DJ, Parker L, Doyle LA, Brown DB. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. J Vasc Interv Radiol 2011;22:1373-9. [PMID: 21764600 DOI: 10.1016/j.jvir.2011.06.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
272 Zhang XB, Wang JH, Yan ZP, Qian S, Liu R. Hepatocellular carcinoma invading the main portal vein: treatment with transcatheter arterial chemoembolization and portal vein stenting. Cardiovasc Intervent Radiol. 2009;32:52-61. [PMID: 18931871 DOI: 10.1007/s00270-008-9454-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
273 Murthy R, Mutha P, Gupta S. Yttrium-90 Radioembolotherapy for Hepatocellular Cancer. In: Mcmasters KM, editor. Hepatocellular Carcinoma:. New York: Springer; 2011. pp. 319-35. [DOI: 10.1007/978-1-60327-522-4_20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
274 Pregler B, Beyer LP, Wiesinger I, Haimerl M, Stroszczynski C, Jung EM, Wiggermann P. Reduced microperfusion due to portal vein thrombosis: Impact on the outcome of percutaneous thermal tumor ablation. Clin Hemorheol Microcirc 2017;67:383-8. [PMID: 28885205 DOI: 10.3233/CH-179218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
275 Palmer DH, Malagari K, Kulik LM. Role of locoregional therapies in the wake of systemic therapy. Journal of Hepatology 2020;72:277-87. [DOI: 10.1016/j.jhep.2019.09.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
276 Gordon AC, Gabr A, Riaz A, Uddin OM, Abouchaleh N, Ali R, Kallini J, Salem R, Lewandowski RJ. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2018;41:1557-65. [PMID: 29948005 DOI: 10.1007/s00270-018-2008-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
277 Zhu M, Jin Z, Hubbard JM. Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers (Basel) 2021;13:651. [PMID: 33561950 DOI: 10.3390/cancers13040651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
278 Shi F, Wang C, Kong Y, Yang L, Li J, Zhu G, Guo J, Zheng Q, Zhang B, Wang S. Assessing the Survival Benefit of Surgery and Various Types of Radiation Therapy for Treatment of Hepatocellular Carcinoma: Evidence from the Surveillance, Epidemiology, and End Results Registries. J Hepatocell Carcinoma 2020;7:201-18. [PMID: 33117754 DOI: 10.2147/JHC.S272813] [Reference Citation Analysis]
279 Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol 2021;12:S361-73. [PMID: 34422400 DOI: 10.21037/jgo.2020.02.08] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
280 Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;151:1155-1163.e2. [PMID: 27575820 DOI: 10.1053/j.gastro.2016.08.029] [Cited by in Crossref: 243] [Cited by in F6Publishing: 209] [Article Influence: 40.5] [Reference Citation Analysis]
281 Gulec SA, Mcgoron AJ. Radiomicrosphere Dosimetry: Principles and Current State of the Art. Seminars in Nuclear Medicine 2022. [DOI: 10.1053/j.semnuclmed.2021.12.009] [Reference Citation Analysis]
282 Li T, Zeng ZC, Wang L, Qiu SJ, Zhou JW, Zhi XT, Yu HH, Tang ZY. Radiation enhances long-term metastasis potential of residual hepatocellular carcinoma in nude mice through TMPRSS4-induced epithelial-mesenchymal transition. Cancer Gene Ther. 2011;18:617-626. [PMID: 21637307 DOI: 10.1038/cgt.2011.29] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
283 Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer Imaging 2012;12:79-88. [PMID: 22487698 DOI: 10.1102/1470-7330.2012.0011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
284 Ghosn M, Derbel H, Kharrat R, Oubaya N, Mulé S, Chalaye J, Regnault H, Amaddeo G, Itti E, Luciani A, Kobeiter H, Tacher V. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. Diagn Interv Imaging 2021;102:35-44. [PMID: 33012693 DOI: 10.1016/j.diii.2020.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
285 Rognoni C, Ciani O, Sommariva S, Tarricone R. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Value Health 2017;20:336-44. [PMID: 28292478 DOI: 10.1016/j.jval.2016.09.2397] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
286 Iñarrairaegui M, Thurston KG, Bilbao JI, D'avola D, Rodriguez M, Arbizu J, Martinez-cuesta A, Sangro B. Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis. Journal of Vascular and Interventional Radiology 2010;21:1205-12. [DOI: 10.1016/j.jvir.2010.04.012] [Cited by in Crossref: 95] [Cited by in F6Publishing: 97] [Article Influence: 7.9] [Reference Citation Analysis]
287 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 251] [Article Influence: 30.9] [Reference Citation Analysis]
288 Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659 [PMID: 27678348 DOI: 10.3748/wjg.v22.i34.7645] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 72] [Article Influence: 12.0] [Reference Citation Analysis]
289 Zhang Y, Li Y, Ji H, Zhao X, Lu H. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis. Biosci Trends 2015;9:289-98. [PMID: 26559021 DOI: 10.5582/bst.2015.01089] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
290 Song MJ, Bae SH. Newer treatments for advanced hepatocellular carcinoma. Korean J Intern Med. 2014;29:149-155. [PMID: 24648795 DOI: 10.3904/kjim.2014.29.2.149] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
291 Tam HH, Al-nahhas A. Treatment of liver tumours with yttrium radioembolisation. Clin Transl Imaging 2014;2:165-82. [DOI: 10.1007/s40336-013-0046-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
292 Riaz A, Lewandowski R, Salem R. Radioembolization in Advanced Hepatocellular Carcinoma. J Clin Oncol 2018;36:1898-901. [PMID: 29718791 DOI: 10.1200/JCO.2018.77.7227] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
293 Lee VH, Leung DK, Luk MY, Tong CC, Law MW, Ng SC, Wong KK, Poon RT, Kwong DL, Leung TW. Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma. Onco Targets Ther 2015;8:3457-64. [PMID: 26640386 DOI: 10.2147/OTT.S92473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
294 Kwon JH, Kim GM, Han K, Won JY, Kim MD, Lee DY, Lee J, Choi W, Kim YS, Kim DY, Han KH. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study. Cardiovasc Intervent Radiol. 2018;41:459-465. [PMID: 29067511 DOI: 10.1007/s00270-017-1826-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
295 Wong W, Cheung C, Mak C. Early experience of transarterial chemoembolization and stereotactic body radiotherapy as neoadjuvant therapy in treating solitary right-lobe hepatocellular carcinoma greater than 10 cm: Large right lobe hepatocellular carcinoma. Surgical Practice 2016;20:43-8. [DOI: 10.1111/1744-1633.12161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
296 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 269] [Article Influence: 27.3] [Reference Citation Analysis]
297 Lau WY, Lai EC, Leung TW. Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review. Int J Radiat Oncol Biol Phys. 2011;81:460-467. [PMID: 20888138 DOI: 10.1016/j.ijrobp.2010.06.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
298 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 183] [Article Influence: 15.2] [Reference Citation Analysis]
299 Johnson GE, Monsky WL, Valji K, Hippe DS, Padia SA. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol 2016;27:1123-9. [PMID: 27321889 DOI: 10.1016/j.jvir.2016.03.046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
300 Vanpouille-Box C, Hindré F. Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity. Front Oncol 2012;2:136. [PMID: 23087900 DOI: 10.3389/fonc.2012.00136] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
301 Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review: Review of International HCC Guidelines. Cancer 2014;120:2824-38. [DOI: 10.1002/cncr.28730] [Cited by in Crossref: 153] [Cited by in F6Publishing: 153] [Article Influence: 19.1] [Reference Citation Analysis]
302 Pasciak AS, Abiola G, Liddell RP, Crookston N, Besharati S, Donahue D, Thompson RE, Frey E, Anders RA, Dreher MR, Weiss CR. The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure. Eur J Nucl Med Mol Imaging 2020;47:816-27. [PMID: 31741021 DOI: 10.1007/s00259-019-04588-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
303 Morise Z, Kawabe N, Tomishige H, Nagata H, Kawase J, Arakawa S, Yoshida R, Isetani M. Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol 2014; 20(39): 14381-14392 [PMID: 25339825 DOI: 10.3748/wjg.v20.i39.14381] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
304 Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol 2014; 20(30): 10223-10237 [PMID: 25132740 DOI: 10.3748/wjg.v20.i30.10223] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
305 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 2013;24:1167-88. [PMID: 23810312 DOI: 10.1016/j.jvir.2013.04.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
306 Dai WC, Cheung TT. Strategic overview on the best treatment option for intrahepaitc hepatocellular carcinoma recurrence. Expert Rev Anticancer Ther 2016;16:1063-72. [PMID: 27548586 DOI: 10.1080/14737140.2016.1226136] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
307 Yu Y, Feng M. Radiotherapy for Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:277-87. [PMID: 30309638 DOI: 10.1016/j.semradonc.2018.06.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
308 Kwee SA, Wong LL, Sato MM, Acoba JD, Rho YS, Srivastava A, Landsittel DP. Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Score-Matched Analysis with Target Trial Emulation. J Vasc Interv Radiol 2021;32:1258-1266.e6. [PMID: 34242775 DOI: 10.1016/j.jvir.2021.07.001] [Reference Citation Analysis]
309 Bodzin AS, Busuttil RW. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol 2015; 7(9): 1157-1167 [PMID: 26019732 DOI: 10.4254/wjh.v7.i9.1157] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
310 Murali N, Mouli SK, Riaz A, Lewandowski RJ, Salem R. Extrahepatic Applications of Yttrium-90 Radioembolization. Semin Intervent Radiol 2021;38:479-81. [PMID: 34629717 DOI: 10.1055/s-0041-1735573] [Reference Citation Analysis]
311 Orsi F, Varano G. Minimal invasive treatments for liver malignancies. Ultrason Sonochem 2015;27:659-67. [PMID: 26050603 DOI: 10.1016/j.ultsonch.2015.05.030] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
312 Chu KKW, Cheung TT. Update in management of hepatocellular carcinoma in Eastern population. World J Hepatol 2015; 7(11): 1562-1571 [PMID: 26085915 DOI: 10.4254/wjh.v7.i11.1562] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
313 Wehrenberg-klee E, Gandhi RT, Ganguli S. Patient Selection and Clinical Outcomes of Y90 in Hepatocellular Carcinoma. Techniques in Vascular and Interventional Radiology 2019;22:70-3. [DOI: 10.1053/j.tvir.2019.02.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
314 Guiu B, Garin E, Allimant C, Edeline J, Salem R. TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. Cardiovasc Intervent Radiol 2022. [PMID: 35149884 DOI: 10.1007/s00270-022-03072-8] [Reference Citation Analysis]
315 Tovoli F, Negrini G, Bolondi L. Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. Hepat Oncol 2016;3:119-36. [PMID: 30191033 DOI: 10.2217/hep-2015-0006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
316 Ozkan ZG, Poyanli A, Ucar A, Kuyumcu S, Akyuz F, Keskin S, Saglam S, Yilmaz E, Karaca C, Turkmen C. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis. Cancer Biother Radiopharm. 2015;30:132-138. [PMID: 25760644 DOI: 10.1089/cbr.2014.1748] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
317 Bolondi L, Cillo U, Colombo M, Craxì A, Farinati F, Giannini EG, Golfieri R, Levrero M, Pinna AD, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, Squadrito G, Toniutto P. Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease 2013;45:712-23. [DOI: 10.1016/j.dld.2013.01.012] [Cited by in Crossref: 103] [Cited by in F6Publishing: 113] [Article Influence: 11.4] [Reference Citation Analysis]
318 Chauhan N, Bukovcan J, Boucher E, Cosgrove D, Edeline J, Hamilton B, Kulik L, Master F, Salem R. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. JMIR Res Protoc 2018;7:e11234. [PMID: 30111528 DOI: 10.2196/11234] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
319 Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010;17:484-91. [PMID: 19876691 DOI: 10.1245/s10434-009-0777-x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 112] [Article Influence: 9.2] [Reference Citation Analysis]
320 Lakhoo J, Perez TH, Borgmann AJ, Brown DB. Lobar Radioembolization for Intermediate and Advanced Hepatocellular Carcinoma: Retrospective and Prospective Data. Semin Intervent Radiol 2021;38:412-8. [PMID: 34629707 DOI: 10.1055/s-0041-1733903] [Reference Citation Analysis]
321 Mahnken AH, Spreafico C, Maleux G, Helmberger T, Jakobs TF. Standards of practice in transarterial radioembolization. Cardiovasc Intervent Radiol. 2013;36:613-622. [PMID: 23511991 DOI: 10.1007/s00270-013-0600-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
322 Osman NMM, Samy LAM. Benign and malignant portal venous thrombosis: Multi-modality imaging evaluation. The Egyptian Journal of Radiology and Nuclear Medicine 2016;47:387-97. [DOI: 10.1016/j.ejrnm.2016.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
323 Ye JZ, Wang YY, Bai T, Chen J, Xiang BD, Wu FX, Li LQ. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update. Oncotarget. 2017;8:93258-93278. [PMID: 29190996 DOI: 10.18632/oncotarget.18735] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
324 Hsieh TC, Wu YC, Sun SS, Yen KY, Kao CH. Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review. Biomedicine (Taipei). 2016;6:19. [PMID: 27848114 DOI: 10.7603/s40681-016-0019-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
325 Moriguchi M, Furuta M, Itoh Y. A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus. J Clin Transl Hepatol 2017;5:177-83. [PMID: 28660156 DOI: 10.14218/JCTH.2016.00075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
326 Baheti AD, Dunham GM, Ingraham CR, Moshiri M, Lall C, Park JO, Li D, Katz DS, Madoff DC, Bhargava P. Clinical implications for imaging of vascular invasion in hepatocellular carcinoma. Abdom Radiol 2016;41:1800-10. [DOI: 10.1007/s00261-016-0763-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
327 Chawla YK, Bodh V. Portal vein thrombosis. J Clin Exp Hepatol. 2015;5:22-40. [PMID: 25941431 DOI: 10.1016/j.jceh.2014.12.008] [Cited by in Crossref: 82] [Cited by in F6Publishing: 59] [Article Influence: 11.7] [Reference Citation Analysis]
328 Kalogeridi MA, Zygogianni A, Kyrgias G, Kouvaris J, Chatziioannou S, Kelekis N, Kouloulias V. Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol 2015; 7(1): 101-112 [PMID: 25625001 DOI: 10.4254/wjh.v7.i1.101] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 11.3] [Reference Citation Analysis]
329 Hickey R, Lewandowski RJ, Salem R. Transarterial Radioembolization (TARE). In: Keefe NA, Haskal ZJ, Park AW, Angle JF, editors. IR Playbook. Cham: Springer International Publishing; 2018. pp. 389-96. [DOI: 10.1007/978-3-319-71300-7_35] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
330 Melstrom LG, Eng OS, Raoof M, Singh G, Fong Y, Latorre K, Choi GH, Salem R, Bentrem DJ, Lewandowski R, Makris E, Poultsides G, Dhar VK, Chadalavada S, Shah SA, Johnson AC, Sekhar A, Kies D, Maithel SK, Rocha F, Alseidi A, Hagendoorn J, Borel Rinkes IHM, Fisher AV, Ronnekleiv-Kelly S, Weber SM, Winslow ER, Abbott DE. Is hepatectomy safe following Yttrium-90 therapy? A multi-institutional international experience. HPB (Oxford) 2019;21:1520-6. [PMID: 31005493 DOI: 10.1016/j.hpb.2019.03.366] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
331 Zhang N, Gu J, Yin L, Wu J, Du MY, Ding K, Huang T, He X. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database. Oncotarget 2016;7:81389-401. [PMID: 27835609 DOI: 10.18632/oncotarget.13232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
332 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
333 Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA 3rd, Kim HS. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21:224-230. [PMID: 20022765 DOI: 10.1016/j.jvir.2009.10.013] [Cited by in Crossref: 128] [Cited by in F6Publishing: 122] [Article Influence: 9.8] [Reference Citation Analysis]
334 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol. 2015;7:738-752. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
335 McGee HM, King MJ, Özbek U, Olson A, Kim E, Fischman AM, Schwartz M, Rosenzweig KE, Buckstein M. Dual Modality Radiation With External Beam Radiation Therapy and Transarterial Radioembolization for Hepatocellular Carcinoma With Gross Vascular Invasion. Am J Clin Oncol 2019;42:367-74. [PMID: 30724782 DOI: 10.1097/COC.0000000000000523] [Reference Citation Analysis]
336 Wachsmann J, Peng F. Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 221-231 [PMID: 26755872 DOI: 10.3748/wjg.v22.i1.221] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
337 Kishi Y, Hasegawa K, Sugawara Y, Kokudo N. Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol. 2011;2011:728103. [PMID: 21994868 DOI: 10.4061/2011/728103] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
338 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
339 Al-Kalbani A, Kamel Y. Y-90 microshperes in the treatment of unresectable hepatocellular carcinoma. Saudi J Gastroenterol. 2008;14:90-92. [PMID: 19568509 DOI: 10.4103/1319-3767.39627] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
340 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
341 Strunk HM. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma. Hepatology 2009;50:652-3. [DOI: 10.1002/hep.23027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
342 Brown ZJ, Hewitt DB, Pawlik TM. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. Expert Opin Investig Drugs 2021;:1-13. [PMID: 34788184 DOI: 10.1080/13543784.2022.2008355] [Reference Citation Analysis]
343 Marrero JA. Viral Hepatitis and Hepatocellular Carcinoma. In: Shetty K, Wu GY, editors. Chronic Viral Hepatitis. Totowa: Humana Press; 2010. pp. 431-47. [DOI: 10.1007/978-1-59745-565-7_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
344 Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F; BLOG (Bologna Liver Oncology Group). Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 2015;35:1036-1047. [PMID: 24750853 DOI: 10.1111/liv.12574] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 8.6] [Reference Citation Analysis]
345 Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Baker T, Kulik L, Gupta R, Abecassis M, Benson AB, Omary R, Millender L, Kennedy A, Salem R. Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization. International Journal of Radiation Oncology*Biology*Physics 2011;79:163-71. [DOI: 10.1016/j.ijrobp.2009.10.062] [Cited by in Crossref: 131] [Cited by in F6Publishing: 109] [Article Influence: 11.9] [Reference Citation Analysis]
346 Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol. 2013;58:609-618. [PMID: 23041304 DOI: 10.1016/j.jhep.2012.09.021] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 9.9] [Reference Citation Analysis]
347 Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, Leung T, Han KH, Poon RT. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84:311-318. [PMID: 23615394 DOI: 10.1159/000348325] [Cited by in Crossref: 91] [Cited by in F6Publishing: 98] [Article Influence: 10.1] [Reference Citation Analysis]
348 Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Integrating Radioembolization (90Y Microspheres) Into Current Treatment Options for Liver Tumors: Introduction to the International Working Group Report. American Journal of Clinical Oncology 2012;35:81-90. [DOI: 10.1097/coc.0b013e3181ec60b8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
349 Iezzi R, Bilhim T, Crocetti L, Peynircioglu B, Goldberg S, Bilbao JI, Sami A, Akhan O, Scalise P, Giuliante F, Pompili M, Valentini V, Gasbarrini A, Colosimo C, Manfredi R. "Primum Non Nocere" in Interventional Oncology for Liver Cancer: How to Reduce the Risk for Complications? Life (Basel) 2020;10:E180. [PMID: 32899925 DOI: 10.3390/life10090180] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
350 Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010;17:1234-1246. [PMID: 20405328 DOI: 10.1245/s10434-010-0977-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
351 Chawla Y, Duseja A, Dhiman RK. Review article: the modern management of portal vein thrombosis. Aliment Pharmacol Ther. 2009;30:881-894. [PMID: 19678814 DOI: 10.1111/j.1365-2036.2009.04116.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 69] [Article Influence: 6.8] [Reference Citation Analysis]
352 Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, Nikolaidis P, Miller FH, Yaghmai V, Baker T, Abecassis M, Benson AB, Mulcahy MF, Omary RA, Salem R. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol. 2012;56:1112-1120. [PMID: 22245905 DOI: 10.1016/j.jhep.2011.11.020] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
353 Padia SA, Lewandowski RJ, Johnson GE, Sze DY, Ward TJ, Gaba RC, Baerlocher MO, Gates VL, Riaz A, Brown DB, Siddiqi NH, Walker TG, Silberzweig JE, Mitchell JW, Nikolic B, Salem R. Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. Journal of Vascular and Interventional Radiology 2017;28:1-15. [DOI: 10.1016/j.jvir.2016.09.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
354 Tong VJW, Shelat VG, Chao YK. Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma. J Clin Transl Res 2021;7:811-33. [PMID: 34988334] [Reference Citation Analysis]
355 Norén A, Urdzik J, Duraj F, Barbier CE, Karlson BM, Haglund U. Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre. HPB (Oxford) 2010;12:637-43. [PMID: 20961372 DOI: 10.1111/j.1477-2574.2010.00210.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
356 Gabr A, Abouchaleh N, Ali R, Vouche M, Atassi R, Memon K, Asadi AA, Baker T, Caicedo JC, Desai K, Fryer J, Hickey R, Abeccassis M, Habib A, Hohlastos E, Ganger D, Kulik L, Lewandowski RJ, Riaz A, Salem R. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. European Journal of Radiology 2017;93:100-6. [DOI: 10.1016/j.ejrad.2017.05.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
357 Teo JY, Allen JC Jr, Ng DC, Choo SP, Tai DW, Chang JP, Cheah FK, Chow PK, Goh BK. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. HPB (Oxford). 2016;18:7-12. [PMID: 26776845 DOI: 10.1016/j.hpb.2015.07.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
358 Sohal DP, Sun W. Hepatocellular carcinoma: prevention and therapy. Curr Oncol Rep. 2011;13:186-194. [PMID: 21409527 DOI: 10.1007/s11912-011-0165-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
359 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3517] [Article Influence: 364.2] [Reference Citation Analysis]
360 Pleguezuelo M, Germani G, Marelli L, Xiruochakis E, Misseri M, Manousou P, Arvaniti V, Burroughs AK. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;2:761-84. [DOI: 10.1586/17474124.2.6.761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
361 Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol. 2012;35:765-774. [PMID: 22648700 DOI: 10.1007/s00270-012-0423-z] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
362 Cappelli A, Pettinato C, Golfieri R. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma 2014;1:163-82. [PMID: 27508185 DOI: 10.2147/JHC.S50472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
363 Lorenzin D, Pravisani R, Leo CA, Bugiantella W, Soardo G, Carnelutti A, Umberto B, Risaliti A. Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization. Cancer Biotherapy and Radiopharmaceuticals 2016;31:65-9. [DOI: 10.1089/cbr.2015.1905] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
364 Yu SJ, Kim YJ. Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World J Hepatol 2015; 7(11): 1553-1561 [PMID: 26085914 DOI: 10.4254/wjh.v7.i11.1553] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
365 Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol. 2011;34:422-431. [PMID: 20622645 DOI: 10.1097/coc.0b013e3181df0a50] [Cited by in Crossref: 63] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
366 Li CC, Chi JL, Ma Y, Li JH, Xia CQ, Li L, Chen Z, Chen XL. Interventional therapy for human breast cancer in nude mice with 131I gelatin microspheres (¹³¹I-GMSs) following intratumoral injection. Radiat Oncol. 2014;9:144. [PMID: 24958442 DOI: 10.1186/1748-717x-9-144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
367 Golfieri R. SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers. Hepat Oncol 2014;1:265-83. [PMID: 30190962 DOI: 10.2217/hep.14.6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
368 Memeo R, de Blasi V, Cherkaoui Z, Dehlawi A, De' Angelis N, Piardi T, Sommacale D, Marescaux J, Mutter D, Pessaux P. New Approaches in Locoregional Therapies for Hepatocellular Carcinoma. J Gastrointest Cancer 2016;47:239-46. [PMID: 27270711 DOI: 10.1007/s12029-016-9840-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
369 Kokabi N, Camacho JC, Xing M, El-rayes BF, Spivey JR, Knechtle SJ, Kim HS. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis: Phase 2 90 Y Therapy in Infiltrative HCC. Cancer 2015;121:2164-74. [DOI: 10.1002/cncr.29275] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
370 Seinstra BA, van Delden OM, van Erpecum KJ, van Hillegersberg R, Mali WP, van den Bosch MA. Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? Insights Imaging. 2010;1:167-181. [PMID: 23100194 DOI: 10.1007/s13244-010-0027-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
371 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
372 Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:563-573. [PMID: 28476736 DOI: 10.6004/jnccn.2017.0059] [Cited by in Crossref: 155] [Cited by in F6Publishing: 149] [Article Influence: 31.0] [Reference Citation Analysis]
373 Ibrahim SM, Lewandowski RJ, Sato KT, Gates VL, Kulik L, Mulcahy MF, Ryu RK, Omary RA, Salem R. Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review. World J Gastroenterol 2008; 14(11): 1664-1669 [PMID: 18350597 DOI: 10.3748/wjg.14.1664] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
374 Han K, Kim JH, Ko GY, Gwon DI, Sung KB. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. World J Gastroenterol 2016; 22(1): 407-416 [PMID: 26755886 DOI: 10.3748/wjg.v22.i1.407] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
375 Sacco R, Conte C, Tumino E, Parisi G, Marceglia S, Metrangolo S, Eggenhoffner R, Bresci G, Cabibbo G, Giacomelli L. Transarterial radioembolization for hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016;3:25-9. [PMID: 27574589 DOI: 10.2147/JHC.S50359] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
376 Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist. 2010;15 Suppl 4:42-52. [PMID: 21115580 DOI: 10.1634/theoncologist.2010-s4-42] [Cited by in Crossref: 102] [Cited by in F6Publishing: 62] [Article Influence: 9.3] [Reference Citation Analysis]
377 Choi BO, Choi IB, Jang HS, Kang YN, Jang JS, Bae SH, Yoon SK, Chai GY, Kang KM. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer. 2008;8:351. [PMID: 19038025 DOI: 10.1186/1471-2407-8-351] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 7.1] [Reference Citation Analysis]
378 Molvar C, Lewandowski RJ. Intra-Arterial Therapies for Liver Masses. Radiologic Clinics of North America 2015;53:973-84. [DOI: 10.1016/j.rcl.2015.05.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
379 Ibrahim SM, Nikolaidis P, Miller FH, Lewandowski RJ, Ryu RK, Sato KT, Senthilnathan S, Riaz A, Kulik L, Mulcahy MF, Omary RA, Salem R. Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging. 2009;34:566-581. [PMID: 18777189 DOI: 10.1007/s00261-008-9454-y] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
380 Chung JW. Recent advance in international management of hepatocellular carcinoma. J Korean Med Assoc 2013;56:972. [DOI: 10.5124/jkma.2013.56.11.972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
381 Sukato DC, Tohme S, Chalhoub D, Han K, Zajko A, Amesur N, Orons P, Marsh JW, Geller DA, Tsung A. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization. Journal of Vascular and Interventional Radiology 2015;26:816-824.e1. [DOI: 10.1016/j.jvir.2015.01.038] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
382 Marin D, Cappabianca S, Serra N, Sica A, Lassandro F, D'Angelo R, La Porta M, Fiore F, Somma F. CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive Review. Gastroenterol Res Pract 2015;2015:670965. [PMID: 26798332 DOI: 10.1155/2015/670965] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
383 Gandhi M, Choo SP, Thng CH, Tan SB, Low AS, Cheow PC, Goh AS, Tay KH, Lo RH, Goh BK, Wong JS, Ng DC, Soo KC, Liew WM, Chow PK; Asia-Pacific Hepatocellular Carcinoma Trials Group. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. BMC Cancer 2016;16:856. [PMID: 27821083 DOI: 10.1186/s12885-016-2868-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
384 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
385 Iavarone M, Colombo M. HBV-related HCC, clinical issues and therapy. Dig Liver Dis. 2011;43 Suppl 1:S32-S39. [PMID: 21195370 DOI: 10.1016/S1590-8658(10)60690-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
386 Rodríguez-fraile M, Iñarrairaegui M. Radioembolization with 90Y-microspheres for liver tumors. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2015;34:244-57. [DOI: 10.1016/j.remnie.2015.05.001] [Reference Citation Analysis]
387 Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB 3rd, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A; Technology Assessment Committee., Interventional Oncology Task Force of the Society of Interventional Radiology. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 2011;22:265-78. [PMID: 21353979 DOI: 10.1016/j.jvir.2010.10.029] [Cited by in Crossref: 148] [Cited by in F6Publishing: 140] [Article Influence: 13.5] [Reference Citation Analysis]
388 Danish FI, Yasmin S. The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia. Hepat Med 2013;5:17-30. [PMID: 24696622 DOI: 10.2147/HMER.S27100] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
389 Edeline J, Gilabert M, Garin E, Boucher E, Raoul JL. Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer 2015;4:16-25. [PMID: 26020026 DOI: 10.1159/000343878] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
390 Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011;259:641-57. [PMID: 21602502 DOI: 10.1148/radiol.11081489] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 12.7] [Reference Citation Analysis]
391 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Locoregional Therapy of Hepatocellular Carcinoma. Clinics in Liver Disease 2015;19:401-20. [DOI: 10.1016/j.cld.2015.01.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
392 Raoul JL, Edeline J, Pracht M, Boucher E, Rolland Y, Garin E. [Radioembolisation for hepatocellular carcinoma]. Cancer Radiother 2011;15:64-8. [PMID: 21236718 DOI: 10.1016/j.canrad.2010.12.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
393 Bauschke A, Altendorf-Hofmann A, Freesmeyer M, Winkens T, Malessa C, Schierz JH, Teichgraeber U, Settmacher U. [Selective internal radioembolization in nonresectable hepatocellular carcinoma]. Chirurg 2016;87:956-63. [PMID: 27460230 DOI: 10.1007/s00104-016-0259-1] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
394 Zhang YF, Guo RP, Zou RH, Shen JX, Wei W, Li SH, OuYang HY, Zhu HB, Xu L, Lao XM. Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. Eur Radiol. 2016;26:2078-2088. [PMID: 26396105 DOI: 10.1007/s00330-015-4021-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
395 Luna Pais H, Alho I, Vendrell I, Mansinho A, Costa L. Radionuclides in oncology clinical practice – review of the literature. Dalton Trans 2017;46:14475-87. [DOI: 10.1039/c7dt01929g] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
396 Gunn AJ, Sheth RA, Luber B, Huynh MH, Rachamreddy NR, Kalva SP. Predicting Outcomes After Chemo-Embolization in Patients with Advanced-Stage Hepatocellular Carcinoma: An Evaluation of Different Radiologic Response Criteria. Cardiovasc Intervent Radiol 2017;40:61-8. [PMID: 27834009 DOI: 10.1007/s00270-016-1451-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
397 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 201] [Article Influence: 36.3] [Reference Citation Analysis]